Cultured Epidermis
Supporting drug development via iPSCs may synergistically serve to advance regenerative medicine. Fujifilm is adjusting its stance with a view to success in both fields and has already achieved significant results in each.
Leveraging the collagen technologies it originally developed for photographic film, Fujifilm has developed a recombinant peptide (RCP), an artificial protein that acts as an effective scaffold on which to grow cells. To facilitate the use of this RCP in research, Fujifilm offers it as the product cellnest in both solution and lyophilized powder form.
In 2014, Japan Tissue Engineering Co., Ltd. became a consolidated Fujifilm Group subsidiary. This company is a pioneer that launched the first two regenerative medicine products to receive approval from the Japanese government. Japan Tissue Engineering currently offers two main products: autologous cultured epidermis JACE® and autologous cultured cartilage JACC®. The company also handles cell culturing work under commission from other companies and institutions. Cellular Dynamics International has also joined the Fujifilm Group and is contributing its extensive knowledge of iPSCs, which are the key to regenerative medicine. The decision to bring these highly innovative companies into the Group further emphasizes Fujfilm’s dedication to achieving leadership in the field of regenerative medicine.
The regenerative medicine market is expected to grow to some USD 120 billion by the 2030s. Yet for Fujifilm, regenerative medicine is much more than an attractive business opportunity. The real significance of engagement in this market lies in curing currently intractable diseases and bringing new hope to sufferers and their loved ones. Aiming to be recognized worldwide as a leader in regenerative medicine, Fujifilm will continue to move forward with this extremely important challenge.